Pulmonary Embolism: Blood Clots in the Lungs
Pulmonary embolism (PE) occurs when a blood clot — most commonly originating in the deep veins of the legs — travels through the venous system and lodges in one or more pulmonary arteries, obstructing blood flow through the lungs. The condition represents a leading cause of cardiovascular mortality in the United States, accounting for an estimated 60,000 to 100,000 deaths annually according to the Centers for Disease Control and Prevention (CDC). This page covers the anatomical mechanism of PE, its classification framework, the clinical contexts in which it arises, and the criteria used to stratify its severity.
Definition and Scope
A pulmonary embolism is classified as a form of venous thromboembolism (VTE), a category that also includes deep vein thrombosis (DVT). The two conditions are closely linked: roughly 50% of patients with DVT develop PE, and PE without an identifiable DVT source is documented in a significant share of cases, suggesting clot formation within the pulmonary vasculature itself or complete clot migration (CDC, Venous Thromboembolism Data & Statistics).
The National Heart, Lung, and Blood Institute (NHLBI) defines pulmonary embolism as a sudden blockage in a lung artery, usually caused by a blood clot that traveled from elsewhere in the body. Classification by anatomical distribution distinguishes three primary forms:
- Saddle PE — A large clot straddling the bifurcation of the main pulmonary artery, obstructing flow to both lungs simultaneously.
- Lobar PE — Clot lodged in a lobar artery supplying one lobe of a lung.
- Subsegmental PE — Smaller clots affecting peripheral subsegmental arteries; clinical significance remains a subject of ongoing evaluation in pulmonary medicine, as detailed across the pulmonary conditions resource index.
The regulatory and clinical management framework for PE is largely governed by guidelines from the American Heart Association (AHA) and the American College of Chest Physicians (ACCP), both of which publish evidence-based protocols for risk stratification and treatment thresholds. The broader legal and reporting context for pulmonary conditions — including VTE-related hospital metrics — is covered at /regulatory-context-for-pulmonary.
How It Works
Under normal physiology, venous blood returns from peripheral tissues to the right side of the heart and is then pumped through the pulmonary arteries into the lung capillaries, where gas exchange occurs. A clot obstructing one or more pulmonary arteries disrupts this circuit through two primary mechanisms:
Hemodynamic obstruction: The physical blockage increases resistance in the pulmonary vascular bed. The right ventricle, which operates at lower pressures than the left ventricle, is poorly adapted to sudden pressure overload. When obstruction is severe, right ventricular failure can occur within minutes to hours.
Ventilation-perfusion (V/Q) mismatch: Obstructed lung segments continue to receive airflow (ventilation) but lose perfusion (blood supply). This mismatch lowers the efficiency of oxygen transfer into the bloodstream, producing hypoxemia — low blood oxygen — that is measurable via pulse oximetry or arterial blood gas analysis.
The extent of physiological disruption depends on clot burden, the patient's underlying cardiopulmonary reserve, and the speed of clot formation. A patient with pre-existing pulmonary hypertension or COPD may decompensate from a clot burden that a healthy individual would tolerate without hemodynamic collapse.
Clot formation itself follows Virchow's Triad, a framework describing three contributing conditions:
- Venous stasis — Slowed blood flow, as occurs during prolonged immobility.
- Endothelial injury — Damage to vessel walls from surgery, trauma, or catheter placement.
- Hypercoagulability — Increased tendency to clot, whether inherited (e.g., Factor V Leiden mutation) or acquired (e.g., malignancy, oral contraceptive use).
Common Scenarios
PE does not arise uniformly across populations. Five high-incidence clinical contexts account for a disproportionate share of cases:
- Post-surgical patients: Orthopedic procedures — particularly total hip and total knee arthroplasty — carry among the highest PE risk of any elective surgery. The ACCP guidelines (Antithrombotic Therapy and Prevention of Thrombosis, 9th edition) address prophylaxis protocols specific to this population.
- Hospitalized and immobile patients: Prolonged bed rest reduces calf muscle pump function, promoting venous stasis in the lower extremities.
- Patients with active malignancy: Cancer-associated thrombosis accounts for approximately 20% of all VTE cases, per data from the National Cancer Institute (NCI).
- Pregnancy and the postpartum period: Hypercoagulable physiological changes during pregnancy elevate PE risk, which peaks in the 6-week postpartum window.
- Long-distance travel: Immobility in confined spaces during flights exceeding 4 hours is associated with increased DVT risk, though absolute risk per flight remains low in healthy travelers.
Shortness of breath is the most common presenting symptom, reported in more than 70% of confirmed PE cases according to the NHLBI. Chest pain, particularly pleuritic pain that worsens with breathing, and unexplained tachycardia are additional hallmark features.
Decision Boundaries
Clinicians stratify PE severity using two intersecting frameworks: anatomical clot burden (assessed via CT pulmonary angiography) and hemodynamic status at presentation.
The most widely adopted classification, as outlined by the European Society of Cardiology (ESC) PE Guidelines (2019), divides PE into three risk tiers:
| Risk Category | Defining Features |
|---|---|
| High-risk (massive) PE | Hemodynamic instability: systolic blood pressure below 90 mmHg, or a drop of ≥40 mmHg for more than 15 minutes |
| Intermediate-risk (submassive) PE | Hemodynamically stable, but evidence of right ventricular dysfunction on imaging or elevated biomarkers (troponin, BNP) |
| Low-risk PE | Hemodynamically stable, no right ventricular dysfunction, low biomarker elevation |
This stratification directly determines treatment pathway. High-risk PE typically warrants systemic thrombolysis or catheter-directed intervention. Intermediate-risk PE requires close monitoring and anticoagulation, with escalation criteria predefined. Low-risk PE may qualify for outpatient anticoagulation management under validated scoring tools such as the Pulmonary Embolism Severity Index (PESI).
Diagnostic thresholds matter equally. A D-dimer blood test carries high sensitivity for ruling out PE in low-probability patients but lacks the specificity to confirm it — a D-dimer below the age-adjusted threshold (age × 10 mcg/L in patients over 50, per the YEARS algorithm and related validated protocols) reduces the need for CT imaging without sacrificing diagnostic accuracy.
The distinction between pulmonary embolism and other causes of acute cardiopulmonary decompensation — including acute pneumonia, pleural effusion, or cardiac-origin dyspnea — requires systematic evaluation of imaging, biomarkers, and clinical probability scores before any treatment threshold is crossed.
References
- Centers for Disease Control and Prevention — Venous Thromboembolism Data & Statistics
- National Heart, Lung, and Blood Institute — Pulmonary Embolism
- National Cancer Institute — Cancer-Associated Thrombosis
- European Society of Cardiology — 2019 ESC Guidelines on Acute Pulmonary Embolism
- American College of Chest Physicians — Antithrombotic Therapy and Prevention of Thrombosis Guidelines
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)